Windsor Financial Group LLC reduced its stake in Pfizer, Inc. (NYSE:PFE) by 7.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 118,433 shares of the biopharmaceutical company’s stock after selling 8,964 shares during the period. Pfizer comprises approximately 1.9% of Windsor Financial Group LLC’s portfolio, making the stock its 29th largest position. Windsor Financial Group LLC’s holdings in Pfizer were worth $4,052,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. Norges Bank purchased a new position in shares of Pfizer during the fourth quarter worth approximately $1,896,890,000. Fisher Asset Management LLC boosted its position in shares of Pfizer by 1.7% in the first quarter. Fisher Asset Management LLC now owns 32,759,530 shares of the biopharmaceutical company’s stock worth $1,120,704,000 after buying an additional 554,777 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of Pfizer by 8.2% in the fourth quarter. Macquarie Group Ltd. now owns 24,455,341 shares of the biopharmaceutical company’s stock worth $794,310,000 after buying an additional 1,845,343 shares in the last quarter. Boston Partners boosted its position in shares of Pfizer by 7.3% in the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after buying an additional 1,649,801 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Pfizer by 1.0% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 17,376,931 shares of the biopharmaceutical company’s stock worth $594,465,000 after buying an additional 169,073 shares in the last quarter. 69.95% of the stock is currently owned by institutional investors and hedge funds.
Pfizer, Inc. (NYSE PFE) opened at 33.64 on Friday. The firm has a 50-day moving average price of $33.38 and a 200-day moving average price of $33.25. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.95. The company has a market capitalization of $200.76 billion, a price-to-earnings ratio of 24.61 and a beta of 1.00.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the business earned $0.64 earnings per share. The business’s revenue was down 1.9% on a year-over-year basis. Analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a $0.32 dividend. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.80%. Pfizer’s payout ratio is 94.12%.
A number of research analysts have recently commented on the company. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Jefferies Group LLC reaffirmed a “neutral” rating and set a $35.00 price target (up previously from $34.00) on shares of Pfizer in a research report on Thursday, April 13th. BMO Capital Markets reaffirmed a “hold” rating and set a $33.00 price target on shares of Pfizer in a research report on Thursday, April 27th. Sanford C. Bernstein reaffirmed a “buy” rating and set a $35.00 price target on shares of Pfizer in a research report on Monday, April 24th. Finally, Credit Suisse Group cut Pfizer from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $38.00 to $36.00 in a research report on Thursday, July 20th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $37.77.
About Pfizer
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
